Dynamic cell cycle kinetics in vitro and in vivo in myelodysplastic syndromes with special reference to the influence of hematopoietic growth factors

Leukemia Research

Volumn 24, Issue 12, 2000, Pages 999-1008

  Holm, Mette ^a   Høyer, Morten ^a   Jensen, Inger ^a   Thomsen, Mette ^a   Hokland, Peter ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cell cycle kinetics; GM CSF administration; Heterogeneity; In vitro growth factor stimulation; Myelodysplastic syndromes; T(s) and T(pot)

Indexed keywords

BROXURIDINE; CELL DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IDOXURIDINE; SCATTER FACTOR;

ADULT; AGED; ARTICLE; CELL HETEROGENEITY; CELL KINETICS; CLINICAL ARTICLE; CONTROLLED STUDY; DNA CONTENT; FEMALE; FLOW CYTOMETRY; GROWTH REGULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL;

AGED; ANTIGENS, CD; BONE MARROW CELLS; CELL CYCLE; DNA; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; IMMUNOPHENOTYPING; LEUKOCYTES, MONONUCLEAR; LEUKOPOIESIS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; TUMOR CELLS, CULTURED;

EID: 0033767653     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00080-1     Document Type: Article

References (53)

1. The smouldering myeloid leukemic states: Clinical and biological features
2. Pathogenesis and clinical variations in the myelodysplastic syndromes
3. Clonal analysis of myelodysplastic syndromes: Evidence of multipotent stem cell origin
4. Medical progress, myelodysplasia
5. Genetic lesions in preleukaemia
6. Evidence for a multistep pathogenesis of a myelodysplastic syndrome
7. Control of growth and normal differentiation in leukemic cells: Regulation of the developmental program and restoration of the normal phenotype in myeloid leukemia
8. Etiopathology, prognosis and therapy of myelodysplastic syndromes
9. Utility of the FAB classification for myelodysplastic syndromes: Investigation of prognostic factors in 237 cases
10. Proposal for the classification of the myelodysplastic syndromes
11. J. international scoring system for evaluating prognosis in myelodysplastic syndromes
12. Myelodysplastic syndromes
13. Effects of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia (AML)) on outcome of AML-type chemotherapy
14. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: A survey by the Leukaemia
15. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome
16. The myelodysplastic syndromes
17. Treatment of myelodysplastic syndromes with hematopoietic growth factors
18. Acute myelogeneous leukaemia and myelodysplasia
19. Myelodysplastic syndromes in the elderly: The role of growth factors in management
20. In vitro growth of myeloid and erythroid progenitor cells from myelodysplastic patients in response to recombinant human granulocyte-macrophage colony-stimulating factor
21. The effects of interleukin-3, GM-CSF, and G-CSF on the growth kinetics of colony-forming cells in myelodysplastic syndromes
22. Impaired response of myelodysplastic marrow progenitors to stimulation with recombinant haematopoietic growth factors
23. Programmed cell death (Apoptosis) in hematopoiesis
24. Regulation of Bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor
25. Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells
26. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
27. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
28. A paradigm shift in myelodysplastic syndromes
29. The proliferative activity of myelopoiesis in myelodysplasia evaluated by multiparameter flow cytometry
30. Optimization of a flow cytometric method for the simultaneous measurement of cell surface antigen, DNA content and in vitro BrdUrd incorporation into normal and malignant hematopoietic cells
31. Dynamic cell cycle kinetics of normal CD34+ cells and CD38+/- subsets of haemopoietic progenitor cells in G-CSF-mobilized peripheral blood
32. Influence of sampling time on assessment on potential doubling time
33. Fas/Apo 1(CD95) expression and apoptosis in patients with myelodysplastic syndromes
34. Apoptosis in myelodysplasia: A paradox or paradigm
35. The myelodysplastic syndromes in 1996: Complex stem cell disorders confounded by dual actions of cytokines
36. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin
37. Apoptosis is a common histopathological finding in myelodysplasia: The correlate of ineffective haematopoiesis
38. Is apoptosis a massive process in myelodysplastic syndromes?
39. Cell cycle kinetic studies in human cancers
40. Cell kinetics in human malignancies studied with in vivo administration of bromodeoxyuridine and flow cytometry
41. CD34+ cells have a lower in vivo labeling index (LI) than CD34 negative cells in myelodysplastic syndromes (MDS)
42. Monoclonal antibody ratios in malignant myeloid diseases: Diagnostic and prognostic use in myelodysplastic syndromes
43. In situ cell cycle kinetics in bone marrow biopsies following sequential infusions of IUdR/BrdU in patients with hematopoietic malignancies
44. Hypothesis: Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome
45. Haemopoietic colony stimulating factors promote cell survival by suppressing apoptosis
46. Control of programmed cell death in normal and leukemic cells: New implications for therapy
47. 'Differentiation therapy' in the myelodysplastic syndromes
48. Treatment of anaemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: Results from randomized phase II study and long-term follow-up of 71 patients
49. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor
50. A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes
51. Clinical use of hematopoietic growth factors in patients with myelodysplastic syndromes
52. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes
53. Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: Evidence for a shortening of the granulocyte release time